Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,338.70 +31.53 0.21%
S&P 500 1,653.28 -2.07 -0.13%
Nasdaq 3,464.56 +1.26 0.04%
Ticker Volume Price Price Delta
STOXX 50 2,776.78 -58.23 -2.05%
FTSE 100 6,696.79 -143.48 -2.10%
DAX 8,351.98 -178.91 -2.10%
Ticker Volume Price Price Delta
Nikkei 14,484.00 -1,143.28 -7.32%
Hang Seng 22,669.70 -591.40 -2.54%
S&P/ASX 200 5,062.45 -102.92 -1.99%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Intercept Pharmaceuticals Inc

+ Add to Watchlist

ICPT:US

34.1600 USD 1.2600 3.83%

As of 14:54:25 ET on 05/23/2013.

Company Profile for Intercept Pharmaceuticals Inc (ICPT)

Intercept Pharmaceuticals Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept Pharmaceuticals serves customers throughout the United States.

Contact Information

Intercept Pharmaceuticals Inc

18 Desbrosses Street
New York, NY 10013
United States
Phone: 1-646-747-1000
Fax: 1-646-747-1001

Key Executives for Intercept Pharmaceuticals Inc (ICPT)

Mark PruzanskiPresident/CEO/Co-FounderBarbara DuncanCFO/Treasurer/Secretary
Luciano AdoriniChief Scientific OfficerDaniel P ReganChief Commercial Officer
David ShapiroExec VP:Dev/Chief Medical Ofcr

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil